



MENARINI
group



COMPANY PROFILE



Menarini was
founded in 1886.

In 1915 its headquarters
were established
in **Florence.**

Milestones

1886

MENARINI FOUNDATION

1964

INTERNATIONAL PRESENCE

The internationalisation of Menarini begins with the opening of **Laboratorios Menarini in Spain**, followed on by **Greece, Portugal, Central America** and **France**.

1978

RESEARCH & DEVELOPMENT

Menarini's Research & Development department opened and patents on pharmaceuticals were introduced.

1992

CENTRAL AND EASTERN EUROPE

Menarini acquires ex-GDR company **Berlin-Chemie** thanks to which it makes its entry into **Germany** and Central and Eastern Europe.

2003

MENARINI BIOTECH

Opening of Menarini Biotech, specialised in the research, development and manufacturing of **biotech pharmaceuticals**, from the lab to the patient.

Milestones



2011

ASIA PACIFIC

Menarini makes its entry into Asia Pacific thanks to the acquisition of a company based in **Singapore** and present in **13 countries** throughout the region, from China to Australia.

2013

SILICON BIOSYSTEMS

Acquisition of Silicon Biosystems, a start-up of innovative technologies for liquid biopsies.

2016

CELLSEARCH

Acquisition of Cell Search, an FDA approved technology in the field of **circulating tumour cells**.


2020

U.S.A.

Menarini makes its entrance into the USA thanks to the acquisition of **Stemline**, biopharmaceutical company publicly listed on NASDAQ, and their product **Elzonris**, the only FDA approved therapy available for BPDCN, thus strengthening Menarini's presence in oncology.

Consolidated turnover


Million euro



Source: internal data. *Source: Iqvia WRMP 12/2021 - Retail Market.

Consolidated turnover


Pharmaceutical **91%**



Diagnostic **8%**

Other **1%**

Abroad **77%**



Italy **23%**

Source: internal data.

Menarini in the **WORLD**

Present in **140 countries** worldwide (with its affiliates, distributors and franchises).



Western Europe



8,500 employees



Presence

Florence - Italy (headquarters), Austria, Belgium, Cipro, France, Germany, Greece, Ireland, Luxembourg, Portugal, Spain, Sweden**, Switzerland, Netherlands**, United Kingdom.



Source: internal data. **Menarini Diagnostics presence.

Central & Eastern Europe



3,400 employees



Presence

Berlin (headquarters), Albania, Armenia, Azerbaijan, Belarus, Bosnia&Herzegovina, Bulgaria, Czech Republic, Croatia, Estonia, Finland, Georgia, Hungary, Kazakhstan, Kyrgystan, Kosovo, Latvia, Lithuania, Moldova, Mongolia, Montenegro, North Macedonia, Poland, Romania, Russia, Serbia, Slovak Republic, Slovenia, Turkmenistan, Ukraine, Uzbekistan.



Source: internal data.

Asia Pacific



3,600 employees



Presence

Singapore (headquarters), China, India, Australia, South Korea, Taiwan, Thailand, the Philippines, Indonesia, Vietnam, New Zealand, Hong Kong and Malaysia.

Source: internal data.

 Distributors – Japan: Menarini Silicon Biosystems presence.

Turkey, Africa & Middle East



1,000 employees



Presence*

Turkey, United Arab Emirates, Saudi Arabia, Egypt, Tunisia



Source: internal data.

*In other countries we are present through distributors

LATAM & Central America

 **1,100 employees****Presence***

Colombia, Costa Rica, Dominican Republic, El Salvador,
Guatemala, Honduras, Mexico, Nicaragua, Panama, Peru

Source: internal data.

*In other countries we are present through distributors

U.S.A.

Stemline

acquisition June 2020

ELZONRIS®
(tagraxofusp)

For the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), commercially available in the US. In Europe, on January 2021 Elzonris was approved by the EMA, as monotherapy for the first-line treatment of adult patients with BPDCN and commercialization started in Europe with the first launch in Germany in July 2021.

Tagraxofusp

is also being evaluated in other CD123+ indications, including chronic myelomonocytic leukemia (CMML), and myelofibrosis (MF).

Other products in Pipeline

SL-701

Immunotherapy in phase II for patients with glioblastoma multiforme.

Felezonexor


XPO1 inhibitor in phase I for patients with advanced solid tumors.

SL-901

PI3K inhibitor in phase I for patients with solid tumors.

SL-10001

RET kinase inhibitor in preclinical development.



Location: New York, U.S.A.

U.S.A and Canada



Menarini Group's lead company in the high-tech diagnostics area.

The main instruments, **DEPArray™PLUS**, **Ampli 1™** and **CELLSEARCH®** are used in personalized oncological therapies to find possible tumor mutations thoroughly and individually, and to determine the best therapy for the patient.

All this from a simple blood sample.


Menarini Silicon Biosystems' latest development is the **new test for the enumeration of multiple myeloma tumor cells in the blood (CMMC)**, which could represent a potential biomarker of the disease. Thanks to the CELLSEARCH technology, minimal residual disease (MRD) could be measured in the future in a minimally invasive way, without the need for bone marrow biopsy.

The new test is already available to American oncologists through the company's CLIA-certified Clinical Laboratory located in Pennsylvania.

 **DEPArray™PLUS** **Ampli1™** **Cell Search®**
Circulating Tumor Cell Test


Locations: Philadelphia, U.S.A.
Bologna, ITALY

Number of employees



Source: internal data.

Employees % of graduates and technicians



18 manufacturing plants

EUROPE is the Group's heart of production

In 2021 **548 million packs** were produced at these sites

Italy

Pisa (2 plants), Florence (2 plants and 1 plant under construction[°]), Pomezia*, L'Aquila, Lomagna (Lecco), Casaleto Lodigiano (Lodi), Rapolano (Siena) plant nearing completion[°]

Spain

Barcelona

Germany

Berlin (2 plants), Dresden

Plants dedicated to the **production for local markets** are located in Central America (Guatemala City), Ireland (Shannon), Turkey (Istanbul), Russia (Kaluga) and Indonesia (Jakarta).

U.S.A. (Philadelphia - Huntingdon Valley): **diagnostic production**



* Biotech manufacturing with development and production processes also for third parties.

[°] Not included in the total number of active plants.

9 Research & Development centres

891 employees



*Pomezia.

Research & Development Projects

ONCOLOGY

COMPOUND	DRUG CLASS (TARGET)	INDICATION	DEVELOPMENT STAGE
Tagraxofusp (Elzonris®)	TB (CD123)	Blastic plasmacytoid dendritic cell neoplasm	EMA and FDA: approved
Tagraxofusp	TB (CD123)	Chronic myelomonocytic leukemia	Phase II
Tagraxofusp	TB (CD123)	Myelofibrosis	Phase II
Elacestrant	SERD (ER)	Breast cancer	Filing*
SL-701	IT (IL-13R α 2, EphA2, Survivin)	Glioblastoma Multiforme	Phase II
MEN1703	SME (PIM/FLT3i)	Acute myeloid leukaemia	Phase II
MEN1611	SME (PI3Ki)	Colorectal cancer	Phase II
MEN1611	SME (PI3Ki)	Breast cancer	Phase Ib
MEN1309	ADC (Anti-CD205)	Solid tumours	Phase Ib
Felezonexor	SME (XPO1i)	Solid tumours	Phase Ib
SL-901	SME (PI3Ki)	Solid tumours	Phase Ia
SL-1001	SME (RETi)	Solid tumours	Preclinical

TB, Targeted Biologic; SERD, Selective Estrogen Receptor Degradar; IT, Immunotherapy; SME, Small Molecule Entity; ADC, Antibody Drug Conjugate.

* Submitted to FDA and EMA

Research & Development Projects **ANTI-INFECTIVES**

COMPOUND	DRUG CLASS	INDICATION	DEVELOPMENT STAGE
Meropenem + Vaborbactam	Carbapenem + β -lactamase inhibitor	Complicated urinary tract infections, Complicated Intra abdominal infections, Hospital acquired pneumonia, Ventilator associated pneumonia and Bacteremia	EMA and FDA: approved
Delafloxacin	Anionic fluoroquinolone	Acute Bacterial Skin and Skin Structure - ABSSSI	EMA and FDA: approved
Delafloxacin	Anionic fluoroquinolone	Community Acquired Bacterial Pneumonia - CABP	EMA* and FDA: approved
Oritavancin	Semisynthetic glycopeptide	Acute Bacterial Skin and Skin Structure - ABSSSI	EMA and FDA: approved
Oritavancin	Semisynthetic glycopeptide	Acute Bacterial Skin and Skin Structure - ABSSSI	Phase Ib (new formulation)

*On April 2021, Delafloxacin has been approved in EU for the for the treatment of CABP.



MENARINI
group

